Dolby Laboratories Financial Statements (DLB) |
||||||||||
Dolby Laboratoriessmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
---|---|---|---|---|---|---|---|---|---|---|
Report date | 16.11.2020 | 17.11.2021 | 30.09.2022 | 18.11.2022 | 17.11.2023 | 17.11.2023 | ||||
Currency | USD | USD | USD | USD | USD | USD | ||||
Financial report URL | ||||||||||
Revenue, bln rub | ? | 1 162 | 1 281 | 1 254 | 1 254 | 376 856 | ||||
Operating Income, bln rub | 218.7 | 344.4 | 206.6 | 206.6 | 74 429 | |||||
EBITDA, bln rub | ? | 332.6 | 464.1 | 320.9 | 329.9 | 109 480 | ||||
Net profit, bln rub | ? | 231.4 | 310.2 | 184.1 | 184.1 | 138 800 | ||||
OCF, bln rub | ? | 343.8 | 447.8 | 318.6 | 318.6 | 310.7 | ||||
CAPEX, bln rub | ? | 69.0 | 54.5 | 47.9 | 59.5 | 23.1 | ||||
FCF, bln rub | ? | 274.9 | 393.3 | 270.6 | 259.1 | 287.6 | ||||
Dividend payout, bln rub | 88.6 | 89.2 | 100.1 | 100.1 | 77.5 | |||||
Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
Dividend payout ratio, % | 38.3% | 28.7% | 54.4% | 54.4% | 0.06% | |||||
OPEX, bln rub | 794.7 | 810.5 | 905.8 | 895.2 | 226 263 | |||||
Cost of production, bln rub | 146.5 | 130.0 | 141.4 | 141.4 | 41 167 | |||||
R&D, bln rub | 239.0 | 253.6 | 261.2 | 261.2 | 68 158 | |||||
Interest expenses, bln rub | 0.186 | 0.479 | 0.394 | 0.394 | 68.1 | |||||
Assets, bln rub | 2 917 | 3 106 | 2 690 | 2 690 | 2 980 | 2 980 | ||||
Net Assets, bln rub | ? | 2 433 | 2 598 | 2 246 | 2 246 | 2 355 | 2 355 | |||
Debt, bln rub | 81.1 | 72.1 | 50.9 | 50.9 | 50.6 | 50.6 | ||||
Cash, bln rub | 1 119 | 1 264 | 809.3 | 809.3 | 884.5 | 884.5 | ||||
Net debt, bln rub | -1 038 | -1 192 | -758.4 | -758.4 | -833.9 | -833.9 | ||||
Ordinary share price, rub | 65.0 | 92.5 | 65.2 | 65.2 | 79.3 | 83.5 | ||||
Number of ordinary shares, mln | 100.6 | 101.2 | 100.0 | 100.0 | 95.7 | |||||
Market cap, bln rub | 6 536 | 9 357 | 6 514 | 6 514 | 0 | 7 986 | ||||
EV, bln rub | ? | 5 498 | 8 165 | 5 756 | 5 756 | -834 | 7 152 | |||
Book value, bln rub | 1 791 | 2 134 | 2 246 | 1 769 | 1 779 | 1 779 | ||||
EPS, rub | ? | 2.30 | 3.07 | 1.84 | 1.84 | 1 450 | ||||
FCF/share, rub | 2.73 | 3.89 | 2.71 | 2.59 | 3.00 | |||||
BV/share, rub | 17.8 | 21.1 | 22.5 | 17.7 | 18.6 | |||||
EBITDA margin, % | ? | 28.6% | 36.2% | 25.6% | 26.3% | 29.1% | ||||
Net margin, % | ? | 19.9% | 24.2% | 14.7% | 14.7% | 36.8% | ||||
FCF yield, % | ? | 4.21% | 4.20% | 4.15% | 3.98% | 0.00% | 3.60% | |||
ROE, % | ? | 9.51% | 11.9% | 8.20% | 8.20% | 0.00% | 5 894% | |||
ROA, % | ? | 7.93% | 9.99% | 6.84% | 6.84% | 0.00% | 4 658% | |||
P/E | ? | 28.2 | 30.2 | 35.4 | 35.4 | 0.06 | ||||
P/FCF | 23.8 | 23.8 | 24.1 | 25.1 | 27.8 | |||||
P/S | ? | 5.63 | 7.30 | 5.20 | 5.20 | 0.02 | ||||
P/BV | ? | 3.65 | 4.38 | 2.90 | 3.68 | 0.00 | 4.49 | |||
EV/EBITDA | ? | 16.5 | 17.6 | 17.9 | 17.4 | 0.07 | ||||
Debt/EBITDA | -3.12 | -2.57 | -2.36 | -2.30 | -0.01 | |||||
R&D/CAPEX, % | 346.5% | 465.8% | 544.9% | 439.3% | 294 776% | |||||
CAPEX/Revenue, % | 5.94% | 4.25% | 3.82% | 4.74% | 0.01% | |||||
Dolby Laboratories shareholders |